Should the healthcare system support health and wellness data tracking for the purposes of long-term observational studies?
Advertisement
The Scientist
Most Recent
Anonymous letters to The Lancet point to problems with the CDC's Center for Global Health, but the agency denies the allegations.
One biopsy may not provide enough information about the array of mutations in cancer to devise treatments based on a tumor’s genetic profile.
NSABB and Congress members voice their opinions about the new developments in the H5N1 research debate.
Two key pieces of legislation, enacted to spur drugmakers into testing pharmaceutical products in children, are up for reauthorization in the US Congress this October. Have they done their jobs?
The Pediatric Research Equity Act (PREA) of 2003 requires that companies developing new drugs that could be used to treat a condition in children perform clinical trials in kids before winning FDA approval. The Best Pharmaceuticals for Children Act (
When children need medications, getting the dosing and method of administration right is like trying to hit a moving target with an untried weapon.
Conspiracy theories surrounding the global HIV/AIDS epidemic have cost thousands of lives. But science is fighting back.
Follow The Scientist
Stay Connected with The Scientist
-
The Scientist Magazine
-
The Scientist Careers
-
Neuroscience Research Techniques
-
Genetic Research Techniques
-
Cell Culture Techniques
-
Microbiology and Immunology
-
Cancer Research and Technology
Current Issue
